Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus LRa05
- Development stage
- Unknown
- Lead developer
- Wecare Probiotics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus LRa05 is a specific probiotic bacterial strain being investigated as a live biotherapeutic product (LBP) for the treatment of metabolic disorders, specifically Type 2 Diabetes Mellitus (T2DM). Developed by researchers at The First Affiliated Hospital of Harbin Medical University, this strain is hypothesized to improve metabolic health by modulating the gut microbiota. Clinical studies are evaluating its efficacy in improving glycemic control (HbA1c and fasting blood glucose), optimizing lipid profiles, and reducing systemic inflammation (C-reactive protein) when used as an adjunctive therapy to standard hypoglycemic agents. The strain is intended to restore microbial balance in the gut, which is thought to influence systemic insulin sensitivity and metabolic homeostasis.
- Other names
- lactobacillus rhamnosus LRa05lacticaseibacillus rhamnosus LRa05
02
Targets
Intestinal mucus and epithelial surface glycansFFAR2
Beyond the preview
Go deeper on lactobacillus rhamnosus LRa05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus LRa05.